Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US2307701092
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000R93GV7
CPIX
Cumberland Pharmaceuticals, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers—Specialty & Generic · THEMEFOLIO: $HLTH
NAME
Cumberland Pharmaceuticals, Inc.
ISIN
US2307701092
TICKER
CPIX
MIC
XNAS
REUTERS
CPIX.OQ
BLOOMBERG
CPIX US
Di., 04.08.2026       Cumberland Pharma
US2307701092

$100 million Strategic Transaction Closed Special Shareholder Dividend FundedAdvancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update followin...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 28.07.2026       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026....
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mo., 13.07.2026       Cumberland Pharma
US2307701092

/C O R R E C T I O N – Cumberland Pharmaceuticals Inc./ In the news release, CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE, issued July 13, 2026 by Cumberland Pharmaceuticals Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional detail...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 01.07.2026       Cumberland Pharma
US2307701092

$100 million Transaction Follows Cumberland Shareholder ApprovalStrengthens Cumberland's Focus on Rare Disease PipelineNASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of Apotex Health Corp. ("Apotex"), the la...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Fr., 26.06.2026       Cumberland Pharma
US2307701092

Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patientsNASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, today shared updated results from its Ph...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2026       Cumberland Pharma
US2307701092

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)Results support development of ifetroban as a cand...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2026       Cumberland Pharma
US2307701092

Commercialization in China through partnership with SciClone PharmaceuticalsExpands access to potentially life-saving antibiotic in the world's second-largest pharmaceutical marketNASHVILLE, Tenn., May 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation focused biopharmaceutical company, today announced the launc...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 05.05.2026       Cumberland Pharma
US2307701092

Enters into Strategic Transaction, unlocking $100 million in valueSharpens focus on Orphan Drug candidates to address unmet medical needsNASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combin...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after the market closes on Tuesday, May 5, 2026. A conference call will be held on May 5 at 4:30 p.m. Eastern...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Cumberland Pharma
US2307701092

Transaction unlocks $100 million in value for Cumberland Sharpens focus on Orphan Drug Candidates to address Unmet Medical NeedsNASHVILLE, Tenn., April 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. specialty pharmaceutical company, today announced it has entered into an agreement with an affiliate of Apotex ("Apot...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 22.04.2026       Cumberland Pharma
US2307701092

New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] as potential add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC)The positive NB data from studies undertaken by Penn State University's Jer...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Cumberland Pharma
US2307701092

A Safe and Effective Non-Opioid Pain Management SolutionNASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its Caldolor® (ibuprofen) Injection pro...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Cumberland Pharma
US2307701092

Sancuso – the Difference Between Life and LivingNASHVILLE, Tenn., March 17, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company today announced the launch of its new Sancuso® (granisetron transdermal system) website. The website is designed to provide health care professionals and patients with e...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 03.03.2026       Cumberland Pharma
US2307701092

Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourt...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 25.02.2026       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., Feb. 25, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today announced the launch of its national sales promotional for Talicia®.  Cumberland has assumed responsibility for the distribution and sales promotion of the br...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026. A conference call will be held on March 3 at 4:30 p.m. Eastern Time to di...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 04.02.2026       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., Feb. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart diseas...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mo., 08.12.2025       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., Dec. 8, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor® (ibuprofen) Injection. The product's permanent J-code, J1741, is now officially associated with a reimbursement price, providing healthcare providers with a CMS-covered, non-opioid option for ma...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $8.3 million during the third quarter of 2025. Year-to-date revenues for the first...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., Oct. 28, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2025 financial results and provide a Company update after the market closes on Tuesday, Nov. 4, 2025....
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 20.10.2025       Cumberland Pharma
US2307701092

 Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focuse...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       Cumberland Pharma
US2307701092

Premier Membership includes 4,350 U.S. Hospitals NASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, has added their potent antibiotic, Vibativ® (telavancin), to a national group pur...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 01.10.2025       Cumberland Pharma
US2307701092

Injectable Ibuprofen Approved for Treating Pain & Fever NASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that its ibuprofen injection product, has received reg...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mo., 29.09.2025       Cumberland Pharma
US2307701092

Vibativ ®  treats patients with pneumonia and serious skin infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia, Sept. 29, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Tabuk Pharmaceutical Manufacturing Company a fu...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., July 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2025 financial results and provide a Company update after the market closes on Tuesday, August 5, 2025....
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mo., 23.06.2025       Cumberland Pharma
US2307701092

New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients NASHVILLE, Tenn., June 23, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company committed to developing new products for rare diseases, shared th...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 27.05.2025       Cumberland Pharma
US2307701092

Analysis Shows 23% Reduction in Morphine Use with Favorable Safety Profile in Patients 60 Years of Age and Older NASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the publication of its study investigating Caldolor® (intravenous ibuprofen) in older pa...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 13.05.2025       Cumberland Pharma
US2307701092

Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial NASHVILLE, Tenn. and CAMBRIDGE, England, May 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced a...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 06.05.2025       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company ge...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 29.04.2025       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financial results and provide a Company update after the market closes on Tuesday, May 6, 2025....
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 19.03.2025       Cumberland Pharma
US2307701092

Ifetroban demonstrated significant 5.4% improvement in cardiac function NASHVILLE, Tenn., March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a l...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 04.03.2025       Cumberland Pharma
US2307701092

2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval  NASHVILLE, Tenn., March 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that i...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 25.02.2025       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a company update after the market closes on Tuesday, March 4, 2025....
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 18.02.2025       Cumberland Pharma
US2307701092

Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 04.02.2025       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mo., 09.12.2024       Cumberland Pharma
US2307701092

-  New Dosing Regimen Simplifies Administration  - NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote®...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 07.11.2024       Cumberland Pharma
US2307701092

–        New Real World Study of 150,000 Patients Favors Caldolor over ketorolac   – –        DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations   – NASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its portfolio of FD...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 06.11.2024       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 05.11.2024       Cumberland Pharma
US2307701092

–        Real World Study Compared Over 150,000 Adult & Pediatric Patients ––        Caldolor Associated with Fewer Adverse Drug Reactions ––        Caldolor also Improved Healthcare Utilization – NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (Nasdaq: CPIX) today announced the publi...
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 31.10.2024       Cumberland Pharma
US2307701092

NASHVILLE, Tenn., Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024....
Zur Nachricht
Cumberland Pharma
Charts & Research Termsheets Terminal
Permalink